The GLP-1 conversation has taken over weight loss medicine. And for good reason — the clinical trial data on semaglutide and tirzepatide is substantial, the results are meaningful, and the compounds have transformed how clinicians think about obesity treatment. But GLP-1 agonists work primarily through appetite suppression and slowed gastric emptying. They don’t specifically target fat metabolism biology. They help people eat less, and the resulting caloric deficit does the work.
There’s a different category of research compounds that work through a different mechanism entirely — directly targeting the fat metabolism pathways rather than appetite signaling. AOD-9604 and Fragment 176-191 are the most studied compounds in this category, and the research literature on both is substantive enough to warrant serious attention from anyone engaged in body composition research.
Free Peptide Research Guide 2026/2027
Download our comprehensive research guide — evidence-based peptide science insights for healthcare practitioners and researchers.
Fragment 176-191: The Lipolysis Research Story
Fragment 176-191 is a stabilized analog of amino acids 176-191 of the C-terminus of human Growth Hormone (hGH). The story behind why this particular fragment is interesting starts with growth hormone itself.
Growth hormone has well-documented effects on body composition — increasing lean body mass and reducing fat mass, particularly visceral fat. But it also has significant effects on blood glucose regulation (primarily through the amino acids 182-189 of the hGH sequence) that create metabolic complications when administered at therapeutic doses. Researchers investigating which part of the hGH sequence was responsible for the fat metabolism effects — and whether it could be separated from the glucose effects — identified the C-terminal fragment as the primary lipolytic region.
Fragment 176-191 was developed from that research: a fragment that retained the fat metabolism signaling of the parent hormone while being substantially inert to the glucose regulation pathways. Preclinical studies — primarily in animal models — have investigated its effects on lipolysis (fat breakdown), fatty acid oxidation, and adipogenesis (new fat cell formation). The research suggests the compound stimulates lipolysis through beta-3 adrenergic receptor pathways while inhibiting lipogenesis, and that these effects appear specific to adipose tissue rather than producing the systemic metabolic disruption associated with full GH administration.
Available through Hello Stacks at research grade for research use only.
AOD-9604: The Regulatory Story and the Research
AOD-9604 (Anti-Obesity Drug 9604) has an unusual regulatory history. It’s the same C-terminal fragment as Fragment 176-191, with a tyrosine group added at position 175 that stabilizes the peptide’s structure and extends its half-life. It went through human clinical trials — Phase IIb and Phase III — under the GRAS (Generally Recognized as Safe) designation in the United States, with trials examining its effects on body weight in obese subjects.
The clinical trial results were mixed in terms of statistical significance on primary endpoints, which accounts for why the compound didn’t advance to approval as a pharmaceutical. But the safety data from human trials is unusually robust for a research-use compound of this type, and the mechanistic research underlying it is well-developed. The preclinical literature on AOD-9604 examines the same lipolytic mechanisms as Fragment 176-191 — beta-3 adrenergic activation, fat-specific effects, and the apparent absence of the glucose-regulatory effects that complicate full GH administration.
Available through Hello Stacks and Stack One at research grade for research use only.
How These Fit Into a Body Composition Research Protocol
The positioning of AOD-9604 and Fragment 176-191 in body composition research is as fat-metabolism-specific compounds — not as GLP-1 alternatives in the clinical sense, but as research tools addressing a different mechanism.
For researchers and practitioners studying body composition in clients who are already on GLP-1 protocols or who’ve completed GLP-1 treatment cycles, these compounds represent an interesting research question: does addressing the fat metabolism pathway directly produce different outcomes than appetite suppression alone? Does the combination address body composition in ways that are additive or complementary?
These are genuine research questions without definitive answers in the published literature yet. What the preclinical data does support is the mechanistic rationale for asking them.
For weight management practices building a research protocol tier, AOD-9604 and Fragment 176-191 represent the “beyond GLP-1” conversation — the protocols that address body composition research questions GLP-1 agonists weren’t designed to answer. Clients who’ve completed GLP-1 cycles and are focused on body recomposition (reducing remaining fat while preserving or building lean mass) represent a growing segment of the weight management client population who are actively looking for what comes next. The research literature on these compounds provides substantive context for that conversation.
What the Research Doesn’t Show
The honest framing that matters: the most robust evidence for both compounds is in animal models. Human clinical data is limited — the AOD-9604 trials provide safety information and some efficacy signals, but the compound didn’t produce statistically significant results on primary endpoints in its most rigorous human trials. Fragment 176-191 has even less human data.
This is consistent with where much of the peptide research landscape sits — compounds with compelling preclinical mechanistic foundations and limited human clinical confirmation. The practitioners and researchers engaging with these compounds are doing so with that understanding: the biology is plausible and well-studied in animal models, human evidence is at an early stage, and the field is moving. That honest framing is what makes the research conversation credible rather than just promotional.
Want to discuss AOD-9604 or Fragment 176-191 in the context of your research protocol design? Reach out to Ted at 725.275.7267 | hellostacks.com | stackone.com
All compounds referenced are for research use only. Not FDA-approved for any clinical application. Nothing here constitutes medical or clinical advice. Consult qualified professionals before implementing any protocol in a clinical setting.